Disrupting the NAD+/NAM metabolic ratio driven by IL-1β inflammatory response potentiates chemotherapy and chemoimmunotherapy in mice
Authors:
Open Access
- 13 October 2026
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Abstract
Nicotinamide adenine dinucleotide (NAD+) replenishment sensitizes tumors to immunotherapy. However, chemotherapy-induced NAD+ metabolic reprogramming remains poorly understood. Here, we show that chemotherapy induces a macrophage-dependent IL-1β inflammatory response and NAD+ metabolic reprogramming, thereby conferring chemoresistance via CD44. Mechanistically, IL-1β-induced NAD+ salvage cooperates with the clearance of nicotinamide (NAM), the physiological inhibitor of the NAD+-consuming enzymes sirtuins, to drive CD44-mediated chemoresistance by boosting the NAD+/NAM ratio for sirtuin activation. NAM phosphoribosyltransferase (NAMPT)-mediated NAD+ salvage recycles NAD+ from NAM and further triggers serine biosynthesis, ultimately supporting NAM N-methyltransferase (NNMT)-mediated NAM clearance. Importantly, NAMPT inhibition disrupts the NAD+/NAM ratio and mitigates CD44-mediated chemoresistance and NK cell dysfunction, ultimately enhancing the efficacy of chemoimmunotherapy when combined with IL-2 across multiple preclinical models of solid tumors. Thus, our findings underscore the NAD+/NAM ratio as a metabolic therapeutic target for enhancing chemotherapy and NK cell-based chemoimmunotherapy efficacy.Keywords
Funding Information
- National Natural Science Foundation of China (82588201)
This publication has 75 references indexed in Scilit:
- CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?Nature Reviews Cancer, 2011
- Immunoselection of Breast and Ovarian Cancer Cells with Trastuzumab and Natural Killer Cells: Selective Escape of CD44high/CD24low/HER2low Breast Cancer Stem CellsCancer Research, 2009
- ELDA: Extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assaysJournal of Immunological Methods, 2009
- DNA repair pathways as targets for cancer therapyNature Reviews Cancer, 2008
- Stat3 up-regulates expression of nicotinamide N-methyltransferase in human cancer cellsJournal of Cancer Research and Clinical Oncology, 2007
- Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survivalHepatology, 2003
- Inhibition of Silencing and Accelerated Aging by Nicotinamide, a Putative Negative Regulator of Yeast Sir2 and Human SIRT1Journal of Biological Chemistry, 2002
- Multiple defects in innate and adaptive immunologic function in NOD/LtSz- scid mice.The Journal of Immunology, 1995
- Eradication of established human melanoma tumors in nude mice by antibody-directed effector cells.Journal of Experimental Medicine, 1985
- Role in nude mice of interferon and natural killer cells in inhibiting the tumorigenicity of human hepatocellular carcinoma cells infected with hepatitis B virusJournal of Clinical Investigation, 1983